Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis

NCT03840148 is registered in ClinicalTrials.gov with Venatorx Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03840148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03840148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 7, 2019
Completion date
December 14, 2021
Enrollment
661 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

acute pyelonephritis, urinary tract infections